Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Mengjiao Wang *Department of Pulmonary and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, People's Republic of China.ORCID http://orcid.org/0009-0003-2513-4662
Li Qiu *Department of Thoracic Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University National Clinical Research Center for Respiratory Diseases, Guangzhou, Guangdong, People's Republic of China tchen01@sibs.ac.cn qbleng@sibs.ac.cn nieyj@hku-szh.org qiuli848@gzhmu.edu.cn.ORCID http://orcid.org/0009-0001-6517-8868
Cheng Tang *State Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0009-0005-4968-4401
Danqing Huang *Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy &Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, Department of Oncology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0009-0001-8911-3874
Qiaocong ZhengState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Zhenhui ZhangDepartment of Thoracic Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University National Clinical Research Center for Respiratory Diseases, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0000-0003-1175-9621
Shupei WeiState Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0009-0003-1312-4993
Lanfang ChenDepartment of Pulmonary and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, People's Republic of China.ORCID http://orcid.org/0009-0002-7031-9060
Hongxin HuangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0000-0002-8656-4266
Jun LiuDepartment of Thoracic Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University National Clinical Research Center for Respiratory Diseases, Guangzhou, Guangdong, People's Republic of China.
Junfeng ZhouState Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0009-0005-0452-464X
Tao LuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.ORCID http://orcid.org/0009-0007-0496-5116
Guanxin LiuDepartment of Pulmonary and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, People's Republic of China.ORCID http://orcid.org/0009-0000-3421-2616
Yingjie NieShenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China tchen01@sibs.ac.cn qbleng@sibs.ac.cn nieyj@hku-szh.org qiuli848@gzhmu.edu.cn.ORCID http://orcid.org/0009-0007-4964-0948
Qibin LengState Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China tchen01@sibs.ac.cn qbleng@sibs.ac.cn nieyj@hku-szh.org qiuli848@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-4768-1312
Tao ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China tchen01@sibs.ac.cn qbleng@sibs.ac.cn nieyj@hku-szh.org qiuli848@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-8433-2509
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundIntratumoral vaccines offer a promising avenue in cancer immunotherapy by harnessing the tumor microenvironment to stimulate immune responses. However, challenges persist in maximizing their effectiveness and addressing immune suppression within tumors.
methodsConventional in situ vaccine (CisVac) and α-CD137 antibody were administered in implanted mouse models of lung and colon cancer to evaluate therapeutic efficacy. The initiation mechanism of CD8
resultsOur findings indicate that this synergistic approach markedly inhibits tumor growth while eliciting a robust antitumor immune response, characterized by heightened activation and cytotoxic differentiation of CD8
conclusionsOur results highlight the transformative potential of the CisVac/α-CD137 combination in cancer immunotherapy, paving the way for further exploration of its clinical utility and long-term efficacy.
Indexed as
Cancer VaccinesCD8-Positive T-LymphocytesDendritic CellsImmunotherapyTumor Necrosis Factor Receptor Superfamily, Member 9AnimalsAntigens, NeoplasmCell CommunicationCell Line, TumorFemaleHumansInflammationMaleMiceAntigens, NeoplasmCancer VaccinesTumor Necrosis Factor Receptor Superfamily, Member 9Combination therapyDendriticSolid tumorToll-like receptor - TLRVaccine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 · full record | OpenQuestion